Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 Jul 6

PMID 34228545

Citations 7

Authors

Vianney Tuloup

Mathilde France

Romain Garreau

Nathalie Bleyzac

Laurent Bourguignon

Michel Tod

Sylvain Goutelle

Affiliations

Soon will be listed here.

Abstract

Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.

Citing Articles

Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT.

Drozd-Sokolowska J, Tridello G, Verheggen I, Karakukcu M, Ben Abdeljelil N, Colita A Bone Marrow Transplant. 2025; .

PMID: 39994334 DOI: 10.1038/s41409-025-02530-4.

Characteristics of and treatment outcomes in rifampicin-intolerant patients.

Mangat R, Brode S, Mah H, Brar M, Sabur N IJTLD Open. 2024; 1(4):160-165.

PMID: 38988405 PMC: 11231820. DOI: 10.5588/ijtldopen.23.0466.

In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022.

Calado Nogueira de Moura V, Nguyen M, Hunkins J, Daley C, Khare R J Antimicrob Chemother. 2023; 78(12):2849-2858.

PMID: 37864515 PMC: 10689928. DOI: 10.1093/jac/dkad317.

Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations.

Osipova N, Budko A, Maksimenko O, Shipulo E, Vanchugova L, Chen W Pharmaceutics. 2023; 15(4).

PMID: 37111743 PMC: 10145013. DOI: 10.3390/pharmaceutics15041258.

Novel approaches in the treatment of Hansen's disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States.

Franco-Paredes C, Garcia-Creighton E, Henao-Martinez A, Kallgren D, Banjade R, Dyer J Ther Adv Infect Dis. 2022; 9:20499361221135885.

PMID: 36387060 PMC: 9647311. DOI: 10.1177/20499361221135885.

References

Ohnhaus E, Brockmeyer N, Dylewicz P, HABICHT H . The effect of antipyrine and rifampin on the metabolism of diazepam. Clin Pharmacol Ther. 1987; 42(2):148-56. DOI: 10.1038/clpt.1987.125. View

Chambers H . Rifabutin to the Rescue?. J Infect Dis. 2020; 222(9):1422-1424. DOI: 10.1093/infdis/jiaa403. View

Aitio M, Mansury L, TALA E, Haataja M, Aitio A . The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol. 1981; 11(3):279-85. PMC: 1401616. DOI: 10.1111/j.1365-2125.1981.tb00535.x. View

Blode H, Zeun S, Parke S, Zimmermann T, Rohde B, Mellinger U . Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. Contraception. 2012; 86(4):337-44. DOI: 10.1016/j.contraception.2012.01.010. View

Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, OReilly T . Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015; 55(9):1012-23. DOI: 10.1002/jcph.510. View

Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M . Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000; 52(10):1265-9. DOI: 10.1211/0022357001777243. View

Natale J, Spinelli T, Calcagnile S, Lanzarotti C, Rossi G, Cox D . Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data. J Oncol Pharm Pract. 2015; 22(3):485-95. PMC: 4843089. DOI: 10.1177/1078155215586824. View

Barditch-Crovo P, Trapnell C, Ette E, Zacur H, Coresh J, Rocco L . The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999; 65(4):428-38. DOI: 10.1016/S0009-9236(99)70138-4. View

Castellan A, Tod M, Gueyffier F, Audars M, Cambriels F, Kassai B . Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet. 2013; 52(3):199-209. DOI: 10.1007/s40262-013-0031-3. View

10.

Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M . Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002; 72(5):505-13. DOI: 10.1067/mcp.2002.129319. View

11.

Backman J, Olkkola K, Neuvonen P . Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996; 59(1):7-13. DOI: 10.1016/S0009-9236(96)90018-1. View

12.

Niemi M, Kivisto K, Backman J, Neuvonen P . Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol. 2001; 50(6):591-5. PMC: 2015006. DOI: 10.1046/j.1365-2125.2000.00295.x. View

13.

Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B . Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011; 50(8):519-30. DOI: 10.2165/11592620-000000000-00000. View

14.

Tugnait M, Gupta N, Hanley M, Sonnichsen D, Kerstein D, Dorer D . Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019; 9(2):214-223. PMC: 7027746. DOI: 10.1002/cpdd.723. View

15.

Schmider J, Brockmoller J, Arold G, Bauer S, Roots I . Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics. 2000; 9(6):725-34. DOI: 10.1097/01213011-199912000-00007. View

16.

Moyle G, Buss N, Goggin T, Snell P, Higgs C, Hawkins D . Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV. Br J Clin Pharmacol. 2002; 54(2):178-82. PMC: 1874397. DOI: 10.1046/j.1365-2125.2002.01631.x. View

17.

Kakuda T, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F . Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother. 2013; 69(3):728-34. DOI: 10.1093/jac/dkt421. View

18.

Lee K, Shin J, Chong W, Kim S, Lee J, Jang I . Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol. 1993; 45(3):287-9. DOI: 10.1007/BF00315399. View

19.

Williamson K, Patterson J, McQueen R, Adams Jr K, Pieper J . Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998; 63(3):316-23. DOI: 10.1016/S0009-9236(98)90163-1. View

20.

Niemi M, Backman J, Fromm M, Neuvonen P, Kivisto K . Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003; 42(9):819-50. DOI: 10.2165/00003088-200342090-00003. View